These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30420858)

  • 1. Baseline Circulating Activated TFH and Tissue-Like Exhausted B Cells Negatively Correlate With Meningococcal C Conjugate Vaccine Induced Antibodies in HIV-Infected Individuals.
    Milagres L; Silva G; Pereira-Manfro W; Frota AC; Hofer C; Ferreira B; Barreto D; Figueredo M; Coelho B; Villela L; Petrovas C; Koup R
    Front Immunol; 2018; 9():2500. PubMed ID: 30420858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ T-cell activation impairs serogroup C Neisseria meningitis vaccine response in HIV-infected children.
    Milagres LG; Costa PR; Santos BA; Silva GP; Cruz AC; Pereira-Manfro WF; Ferreira B; Barreto DM; Frota AC; Kalil J; Hofer CB; Kallas EG
    AIDS; 2013 Nov; 27(17):2697-705. PubMed ID: 24149087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of serum bactericidal antibody and opsonic antibody levels after Neisseria meningitidis serogroup C conjugate vaccine in Brazilian children and adolescents infected or not infected with HIV.
    Pereira-Manfro WF; Alvino RM; Cruz AC; Silva GP; Castro RB; Ferreira B; Barreto DM; Frota AC; Hofer CB; Milagres LG
    Vaccine; 2016 Dec; 34(50):6116-6119. PubMed ID: 27847176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsets of memory CD4+ T cell and bactericidal antibody response to Neisseria meningitidis serogroup C after immunization of HIV-infected children and adolescents.
    Milagres LG; Costa PR; Silva GP; Carvalho KI; Pereira-Manfro WF; Ferreira B; Barreto DM; Frota AC; Hofer CB; Kallas EG
    PLoS One; 2014; 9(12):e115887. PubMed ID: 25532028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Peripheral T Follicular Helper Cells in Perinatally HIV-Infected Children Correlate With Advancing HIV Disease.
    McCarty B; Mwamzuka M; Marshed F; Generoso M; Alvarez P; Ilmet T; Kravietz A; Ahmed A; Borkowsky W; Unutmaz D; Khaitan A
    Front Immunol; 2018; 9():1901. PubMed ID: 30197641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
    Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
    Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
    J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
    Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
    Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between circulating exhausted CD4+ T cells with poor meningococcal C conjugate vaccine antibody response in HIV-infected children and adolescents.
    Silva GP; Pereira-Manfro WF; Costa PR; Costa DA; Ferreira B; Barreto DM; Frota ACC; Hofer CB; Figueredo CM; Coelho B; Kallas EG; Milagres LG
    Clinics (Sao Paulo); 2021; 76():e2902. PubMed ID: 34614112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
    Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
    Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
    Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
    Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults.
    Bertolini DV; Costa LS; van der Heijden IM; Sato HK; Marques HH
    Vaccine; 2012 Aug; 30(37):5482-6. PubMed ID: 22771509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?
    Stoof SP; Buisman AM; van Rooijen DM; Boonacker R; van der Klis FR; Sanders EA; Berbers GA
    PLoS One; 2015; 10(10):e0138665. PubMed ID: 26458006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
    Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
    Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.